Cellectis has 25 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile. The company develops a new generation of immunotherapy product candidates with additional safety and efficacy attributes equipped to resist mechanisms that inhibit immune system activity. The allogeneic CAR-T approach offers significant competitive advantages over standard autologous therapies.
Cyborg Score Rationale
Recent Phase 1 BALLI-01 study data for lasme-cel (UCART22) demonstrated 68-100% efficacy rates depending on dose escalation. The company has strong intellectual property and technology platforms. However, as a clinical-stage company, Cellectis faces execution risk and cash burn concerns typical of pre-revenue biotech.
Top Insights
UCART22 (lasme-cel) Phase 1 data showed 68% overall response rate and up to 100% efficacy in target Phase 2 population
Cellectis' allogeneic approach uses T-cells from healthy donors with gene editing to disable genes causing graft-versus-host disease, offering off-the-shelf manufacturing advantages
Recently published Nature Communications article establishing circular single-stranded DNA (CssDNA) as efficient non-viral gene insertion platform for hematopoietic stem cells
Company maintains strong cash position of $264 million as of September 30, 2024, with strategic collaborations including AstraZeneca
Named Competitors
Autologous CAR-T therapies — Traditional patient-derived CAR-T cell therapies